Equels Thomas K
Company insiders · CEO & President · Director · AIM ImmunoTech Inc.
- Reported transaction lines
- 8
- Buy lines
- 8
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-118
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 436095 · SEC code covers open-market or private transactions | 2026-11-19 | 2026-11-20 | ≈ $6,550.00 50,000 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 386095 · SEC code covers open-market or private transactions | 2026-11-18 | 2026-11-18 | ≈ $2,680.00 20,000 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 366095 · SEC code covers open-market or private transactions | 2026-11-16 | 2026-11-17 | ≈ $5,130.00 38,000 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 328095 · SEC code covers open-market or private transactions | 2026-11-11 | 2026-11-13 | ≈ $5,215.00 35,000 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 293095 · SEC code covers open-market or private transactions | 2026-11-10 | 2026-11-12 | ≈ $5,382.00 39,000 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 254095 · SEC code covers open-market or private transactions | 2026-11-09 | 2026-11-10 | ≈ $5,070.28 31,298 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 222797 · SEC code covers open-market or private transactions | 2026-11-06 | 2026-11-09 | ≈ $2,014.66 12,751 shares/units | SEC 4 |
| Equels Thomas K CEO & President · Director · AIM ImmunoTech Inc. | AIM AIM ImmunoTech Inc. | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 210046 · SEC code covers open-market or private transactions | 2026-11-06 | 2026-11-06 | ≈ $3,166.64 20,299 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.